Ghassan El-Haddad, MD

07/23/2021

CIO 2020-2 Safety of Sequential Bland Embolization - PRRT in Patients With Metastatic Neuroendocrine Tumors

Dhiraj Sikaria , MD;

Jonathan Strosberg , MD;

Jose Jesurajan , MD;

Ghassan El-Haddad , MD;

07/23/2021

Prevention and Medical Management of Carcinoid Crisis During Bland Embolization for Neuroendocrine Tumor

Ghassan El-Haddad, MD, H. Lee Moffitt Cancer Center & Research Institute, discusses the prevention and medical management of carcinoid crisis during bland embolization for neuroendocrine ...

Ghassan El-Haddad , MD;

07/28/2021

My Approach to Neuroendocrine Tumor

Ghassan El-Haddad , MD;

02/04/2022

Liver Disease Audience Q&A

Note: This audience Q&A concludes Session 2: My Approach to Liver Disease

Ghassan El-Haddad , MD;

Yolanda Bryce , MD, RPVI;

Constantinos T. Sofocleous , MD, PhD, FSIR;

Susan Shamimi-Noori , MD;

02/04/2022

Medical Management and Prevention of Carcinoid Crisis During Bland Embolization for Neuroendocrine Tumor

Ghassan El-Haddad , MD;

02/07/2022

CIO 2021-5 Y-90 Radioembolization for Neuroendocrine Tumor Liver Metastases and Periprocedural Hemodynamic Instability

Purpose: Transarterial radioembolization (TARE) is commonly used for treatment of neuroendocrine tumor liver metastases (NETLMs). Hormonal release causing hemodynamic instability and carc...

A. Weekley ;

Bela Kis ;

Jonathan Strosberg , MD;

Ghassan El-Haddad , MD;

11/15/2021